Peptides for eating disorders: the appetite and reward approach

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

Eating disorders are complex, often involving dysregulation of appetite and reward pathways. Peptides like GLP-1 agonists, BPC-157, and Oxytocin show promise by modulating these systems, offering novel therapeutic avenues beyond conventional approaches.

Peptides for Eating Disorders: The Appetite and Reward Approach

Approximately 9% of the U.S. population, or 28.8 million Americans, will experience an eating disorder in their lifetime, with high comorbidity rates for anxiety and depression. Traditional treatments, while effective for some, often struggle with relapse rates and addressing the underlying neurobiological mechanisms driving disordered eating behaviors. We're observing a growing interest in peptide therapeutics that directly target appetite regulation, satiety signaling, and reward pathways within the central nervous system.

GLP-1 Agonists: Modulating Satiety and Food Cravings

Glucagon-like peptide-1 (GLP-1) agonists, such as semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda, Victoza), are well-established for their roles in diabetes and weight management. Their mechanism involves activating GLP-1 receptors in the brain, particularly in the hypothalamus and brainstem, to enhance satiety and reduce food intake. Clinically, we've seen patients prescribed semaglutide for obesity report a significant decrease in cravings for highly palatable, energy-dense foods, often within 4-6 weeks of initiation. For instance, a typical starting dose of 0.25 mg semaglutide subcutaneously once weekly, titrating up to 2.4 mg over 16-20 weeks, can profoundly alter eating patterns. This isn't just about gastric emptying; it's about altering the hedonic response to food. A 2023 study by Dr. Müller and colleagues at the Max Planck Institute demonstrated that GLP-1 receptor activation directly reduces dopamine release in the nucleus accumbens in response to anticipated food cues, effectively dampening the reward signal associated with eating.

While highly effective for binge eating disorder (BED) or obesity co-occurring with disordered eating, GLP-1 agonists require careful consideration in patients with anorexia nervosa or those with a history of restrictive eating, as their potent appetite-suppressing effects could exacerbate weight loss and malnutrition. You wouldn't prescribe a GLP-1 agonist to someone actively restricting; that's just poor clinical judgment. However, for a patient struggling with uncontrolled binge eating, often driven by intense cravings and a dysregulated reward system, it's proving to be a powerful tool.

BPC-157: Gut-Brain Axis Repair and Mood Stabilization

Body Protection Compound-157 (BPC-157) is a gastric pentadecapeptide that has garnered attention for its regenerative and anti-inflammatory properties, particularly within the gastrointestinal tract. What's often overlooked in eating disorder contexts is its potential to modulate the gut-brain axis and influence mood. Disordered eating frequently leads to gut dysbiosis and inflammation, which in turn can perpetuate anxiety and depression. BPC-157, typically administered at 250-500 mcg subcutaneously twice daily for 4-8 weeks, can accelerate the healing of intestinal lining damage, reduce systemic inflammation, and normalize neurotransmitter systems like serotonin and dopamine, as suggested by animal studies from Dr. Sikiric's lab dating back to 2004. We've observed that patients with long-standing bulimia nervosa or BED who present with significant GI distress (e.g., irritable bowel symptoms, chronic constipation) often report improved mood and reduced anxiety alongside gut symptom resolution when BPC-157 is part of their regimen. It's not a direct appetite modulator like GLP-1, but it indirectly supports mental well-being and gut integrity, crucial components in recovery.

Oxytocin: Enhancing Social Bonding and Reducing Anxiety

Oxytocin, often dubbed the 'love hormone,' plays a critical role in social bonding, trust, and anxiety reduction. In the context of eating disorders, especially those with strong social or emotional components like anorexia nervosa and bulimia nervosa, oxytocin's anxiolytic and prosocial effects are particularly relevant. Studies have shown that intranasal oxytocin, typically at doses of 24-40 IU once or twice daily, can reduce food-related anxiety and improve body image dissatisfaction in patients with anorexia nervosa, as reported by Dr. Deborah Mitchison's research group in 2017. It appears to normalize the reward response to social stimuli over food, potentially decreasing the salience of food-related cues that trigger restrictive or compensatory behaviors. Unlike GLP-1 agonists that directly suppress appetite, oxytocin works by shifting focus and reducing the emotional burden associated with food and body image. It's not about forcing someone to eat or stop eating; it's about creating a more stable emotional landscape where they can engage more effectively with therapy and make healthier choices.

Peptide Therapy vs. Conventional Approaches

When you compare peptide therapy to conventional pharmacotherapy like SSRIs, you'll see a fundamental difference. SSRIs primarily target serotonin reuptake, aiming to stabilize mood, which can indirectly impact eating behaviors. However, they don't directly address the complex interplay of appetite, satiety, and reward signaling with the precision that peptides offer. For instance, while an SSRI might reduce general anxiety in a bulimic patient, it won't directly modulate their hedonic response to highly palatable foods in the same way a GLP-1 agonist would. Similarly, cognitive-behavioral therapy (CBT) is foundational, but peptides can create a more receptive neurobiological environment for CBT to be effective. It's not an 'either/or' situation; it's about integrating these novel biological tools into a comprehensive, multidisciplinary treatment plan.

For example, a patient with BED might benefit from semaglutide to control binges, BPC-157 to heal their inflamed gut, and concurrent CBT to address psychological triggers. This combined approach often yields superior outcomes than monotherapy. The nuance here is crucial: peptides aren't a standalone cure, but powerful adjunctive agents that target specific physiological dysregulations that underpin eating disorders.

A specific clinical takeaway: For patients presenting with binge eating disorder and significant food cravings, consider initiating a low-dose GLP-1 agonist like semaglutide (0.25 mg weekly, titrating up), while simultaneously assessing for gut-brain axis dysfunction, which may warrant a course of BPC-157 (250 mcg BID subcutaneously for 6-8 weeks) to optimize therapeutic response and overall well-being.